The Cost of Cancer-Related Physician Services to Medicare

Sean Maroongroge, ScB; Simon P. Kim, MD, MPH; Sarah Mougalian, MD; Kimberly Johung, MD, PhD; Roy H. Decker, MD, PhD; Pamela R. Soulou, MPH; Jessica B. Long, MPH; Cary P. Gross, MD; and James B. Yu, MD, MPH*

Yale School of Medicine, New Haven, Connecticut; University Hospital Case Western Reserve Medical Center, Case Western Reserve University, Cleveland, Ohio; Department of Therapeutic Radiology, Yale School of Medicine, New Haven, Connecticut; Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut; Cancer Outcomes, Public Policy, and Effectiveness Research (COPPER) Center, Yale University, New Haven, Connecticut

INTRODUCTION

Approximately $124 billion was spent on cancer-related costs in 2010, and as the U.S. population ages, it is likely that this figure will continue to grow [1]. Currently, 1 in 12 dollars spent in the Medicare Fee-For-Service (FFS) Program is spent on cancer care [2]. One of the larger components of this spending is for physician and supplier services [3]. Cancer spending in particular is disproportionately focused on physician services compared to other disease states [2], though no recent analysis has been performed on this significant subset of cancer spending.

Although physician services represent a substantial portion of cancer care costs, little is known about trends in the costs of physician cancer services in the fee-for-service Medicare program. We analyzed aggregated data from all Part B Medicare claims for physician and supplier services attributed to cancer patients from 1999 to 2012 to characterize how billing and payments have changed over time for the most common cancer types. Billing and expenditure data are from the Medicare Statistical Supplement, and age-adjusted incidence data are from SEER. Physician services for cancer patients grew from $7.6 billion in 1999 to $12.3 billion in 2012 (60 percent increase). Reimbursements for physician and supplier services for cancer treatment in Medicare Part B beneficiaries steadily grew from 1999 to 2005 and then plateaued through 2012, led by a decrease in reimbursements for prostate cancer care. These trends may reflect shifts toward hospital-based care or changes in aggressiveness of care.

**“Physician services” is a technical term used to describe a specific set of expenditures covered by the Medicare Part B program. When a provider performs a treatment for a patient, Medicare Part B reimburses that physician for his or her time [4]. Additional payments may be included for drugs administered by a physician that a physician must purchase beforehand or if the physician is performing the procedure in his or her own office. Finally, supplier services, which constitute non-durable equipment like bandages, are sometimes analyzed in this category as well, though these are not paid to the physician [3]. Our analysis is limited to physician and supplier services,**
which represent a sizeable proportion of cancer expenditures. In 2011, physician services composed 41 percent of total Medicare expenditures for cancer care, compared to 25 percent for outpatient hospital fees, and 22 percent for inpatient hospital fees. Hospice, home health, and skilled nursing facilities constituted the rest [2].

Although recent debate over the Sustainable Growth Rate has led to an increased scrutiny of physician services, little is known about how physician expenditures have grown for cancer care in particular [5]. A descriptive analysis of these expenditures over the past decade provides the background for an informed discussion of payment reform affecting physician reimbursement. Furthermore, comparing the amount physicians charge to Medicare to the amount Medicare actually reimburses the physicians may reveal a disconnect between physician-defined value and the government’s willingness to pay. At the least, a growing divide between physician charges and actual Medicare payment may reflect the current reality in which physician charges are increasingly independent from what is actually reimbursed. Since some private insurers use actual physician charges to determine physician reimbursement and as many providers directly bill charges to uninsured patients [6], a growing difference between the charged and reimbursed amount could represent containment of health care expenditures via Medicare’s fee schedule relative to the amount reimbursed by other payers.

The overall cost of cancer treatment varies by cancer type due to differing incidence rates, types of treatments, and treatment costs [1]. Though prior studies of cancer spending over time have focused on individual disease sites [7-9], treatment modalities [10], or earlier periods [11,12], this paper analyzes how Medicare’s physician charges and payments have changed for cancer services overall and for the most common cancer types (colorectal, female breast, lung, and prostate cancers) over the past decade. In 2010, these cancers made up half of all new cancers reported in the United States [13]. By isolating physician expenditures, we are able to characterize general trends affecting an important subset of cancer expenditures over the past decade.

METHODS

Overview

Medicare reimbursements for physician services in oncology are complex because physicians must purchase physician-administered drugs and are reimbursed for the cost of the drug after therapy. Our analysis, therefore, includes payments to physicians for the services they provide and the cost of most chemotherapy used to treat patients.

We combined recent spending and incidence data to examine national cancer costs for physician services to Medicare’s Part B Program. Notably, we did not have data regarding costs charged by and reimbursed to hospital-based outpatient facilities and, therefore, have focused on physician service and supplier costs. We controlled for case number to focus on cost growth due to technology development, care intensity, and reimbursement rates. We further compared submitted charges with the amounts reimbursed by Medicare to measure how provider-defined costs differ from payer-defined costs. Although charges do not directly correlate with Medicare payments in a given year, they are incorporated into several Medicare reimbursement policies, and they serve as reference points for hospital payment negotiations with non-Medicare private insurers and the uninsured [6].

Study Design

First, we examined trends in the number of beneficiaries from the Medicare enrollment reports to provide context for changes in cancer case number and spending [14]. Next, we obtained national spending data from the Medicare Statistical Supplement [3]. Then we used incidence data from the Surveillance, Epidemiology, and End Results (SEER) databases of the National Cancer Institute to estimate the total number of new cancer cases in the Medicare Part B program each year [15] so we could compare the physician expenditures per case across cancer sites. We also examined how submitted charges varied with payments for each site. Finally, we report descriptive statistics to describe the trends over time.

Data Sources

We retrieved cancer incidence data from the SEER 13 database, submitted in November 2013, using SEER*Stat software [15,16]. The data represent approximately 13.4 percent of the population. Cancer types were identified by International Classification for Diseases — Oncology — Version 3 (ICD-0-3) code [17].

We used the Medicare Statistical Supplement [3] to collect data on the provider-submitted charges and Medicare Part B physician program payments each year for all cancers and female breast, prostate, lung and colorectal cancer. The Statistical Supplement is an annual report published by the CMS Office of Information Products and Data Analysis (OIPDA) that covers calendar years 1999-2012. CMS aggregated all finalized physician and supplier claims that were billed with a primary International Classification of Diseases (ICD-9-CM) diagnosis code for cancer, and our analysis focuses on these aggregated figures. The data are abstracted from the Carrier Standard Analytical File, a compilation of non-institutional claims by physicians, non-physician practitioners, laboratories, and ambulances [18]. These services represent just a subset of Part B expenditures because facility fees in the outpatient hospital setting are excluded [19]. The charge data and payment data both reflect the same patient population (the entirety of Part B physician charges and payments attributed to each cancer).

Due to data limitations, breast cancer statistics are limited to female patients. Lung cost data represent trachea, bronchus, and lung cancers, whereas lung incidence
data also include primary mediastinal tumors and other unspecified respiratory neoplasms. Exact coding specifications used are listed in Table 1.

**Estimating the Number of Incident Cancers Among Medicare FFS Beneficiaries**

Because the Medicare Statistical Supplement does not provide data on the number of beneficiaries treated for each disease, we needed to estimate the number of Medicare FFS beneficiaries diagnosed with cancer in each year examined. We estimated this number by multiplying incidence data from SEER with the total number of Medicare beneficiaries enrolled in Part B each year. Annual Part B beneficiary counts were obtained from Medicare Enrollment reports [14]. We used delay-adjusted incidence data from SEER to overcome expected delays in cancer registry reporting.

Because Medicare provides coverage for both the aged (age 65 and over) and disabled (under age 65), we used SEER*Stat to calculate separate incidence rates for the population older than age 65 and the population younger than age 65. We multiplied the SEER-derived cancer incidence rates for the population over 65 by the total number of FFS beneficiaries over age 65. We repeated this for the populations under age 65. We then summed these figures to estimate the total number of new cancer cases among Medicare part B beneficiaries each year. Our model for cancer incidence therefore excludes Medicare Advantage beneficiaries, so spending and incidence data focus only on FFS Medicare.

In order to obtain accurate estimates of Part B female breast and prostate cancer case numbers, we estimated the number of female and male enrollees by multiplying the total number of Part B enrollees by the gender ratio of beneficiaries who received physician and supplier services [3].

**Cost of Care**

The Medicare expenditures for each cancer type (compiled by Medicare based on each claim’s primary ICD-9 diagnosis code) were directly obtained from the Medicare Statistical Supplement [3]. As noted previously, the examined values only include physician and supplier expenditures for Medicare Part B and therefore exclude hospital facility fees. All costs were adjusted for inflation to 2011 dollars using the historical consumer price index (CPI) for all urban consumers [20]. To calculate the cost per incident cancer, we divided the annual costs attributable to each cancer type by the estimated number of new cancers diagnosed for each year.

**Statistical Analysis**

We first report descriptive statistics describing changes in enrollment demographics and cancer incidence across all sites. Next, we examined costs in each cancer type, adjusting for the number of incident cases in a year. Finally, we used available data on submitted charges and program payments to explore the role of incidence and reimbursement policies on Medicare physician expenditures over time.

**RESULTS**

**Trends in the Number of New Cancer Cases and Medicare Beneficiaries**

Although the overall number of new cancer cases stayed within 5 percent of its 1999 value, there was large site-specific variation (Figure 1). The number of colon cancer cases fell 26.6 percent over the study period. The number of prostate cancer cases decreased 16.7 percent overall over the study period. The number of lung cancer cases remained fairly constant, whereas the estimated number of breast cancer diagnoses decreased 10 percent and subsequently returned to 1999 levels by 2011.

This occurred during a time of a steady growth in Medicare FFS beneficiaries from 37 million to over 45 million [14]. The disabled (under age 65) population became a larger proportion of those enrolled in the Medicare
FFS program, representing 12.5 percent of total enrollees in 1999 and 18 percent of total enrollees by 2011.

Physician Service Expenditures

The overall cost of physician services due to all neoplasms grew from $7.6 billion CPI-adjusted dollars in 1999 to $12.3 billion CPI-adjusted dollars in 2012. The trend in costs varied according to cancer type (Figure 2). Prostate cancer spending declined from a maximum of over $2 billion CPI-adjusted dollars in 2003 to its lowest value of just over $1.3 billion in 2012. Other cancer sites tended to share a pattern of moderate growth over time, with relative increases during the study period of 29 percent for lung, 80 percent for breast, and 105 percent for colon.

Our estimates of yearly physician expenditures per cancer case also show notable variation by cancer site (Figure 3). Although the Medicare physician cost of prostate cancer per case started off highest in 1999 and grew at comparable rates with the other cancer types, it steeply declined from 2003 to 2005. In contrast, all other cancer types examined showed a growth period from 1999 to 2004 and then a relative plateau through 2011. Colon and breast cancer reimbursements per newly diagnosed patient showed the largest increases during the study period.
Comparison of Submitted Charges to Medicare and Resultant Payments

For every disease site, provider charges and the associated program payments began growing at a slower rate at some point from 2006 to 2011. However, prostate cancer program payments showed an additional source of stabilization: a rapid decline in the proportion of charges that were reimbursed. Program payments in prostate cancer sharply fell from 2004 to 2005, even though the submitted charges continued to grow. In contrast, colon cancer program payments for physician services trended much more closely with the amount billed, contributing in part to the 150 percent increase in colon cancer program payments from 1999 to 2005. Over the entire period, the reimbursed fraction of submitted charges fell only 6 percent for colon cancer, but 14 percent for prostate cancer (Figure 4).

The growth in both breast cancer program payments and submitted charges appeared to slow from 2006 to 2011. Nevertheless, program payments almost doubled from 1999 to 2011, while the number of incident cases was nearly identical in the first and last years.
After prostate cancer, lung cancer showed the least growth in program payments over the course of study, with only a 29 percent increase.

DISCUSSION

Although the number of beneficiaries grew each year, the estimated number of Medicare fee-for-service beneficiaries newly diagnosed with cancer decreased over the study period, driven largely by declining prostate and colon cancer incidence rates. The declining incidence rates likely represent increased colonoscopy screening (and the removal of pre-cancerous polyps) and decreased prostate cancer screening [21,22]. At the same time, the physician service-related cost per case showed steady growth over the first part of the study period but leveled off from 2005 to 2011. Part of the stabilization of cancer care costs was due to the decreasing cost of prostate cancer care.

Compared to 1999 values, the overall cost of physician services as measured by Medicare program payments decreased more for prostate cancer than for other cancer types. There are two possible reasons for this decline. The first explanation is a decline in the cost of care. This is consistent with other reports, indicating that the average cost to Medicare per common surgical and radiation-based prostate cancer treatment declined significantly from 2002 to 2005 [8]. One influential payment policy change that occurred at that time was the Medicare Modernization Act (MMA) of 2003, which reduced the effective reimbursement for androgen deprivation therapy (ADT) drugs by over 50 percent from 2003 to 2005 [23,24].

The second possible contributor to the overall decline in reimbursement is that practice patterns changed to favor less costly treatment. Though more expensive techniques such as minimally invasive radical prostatectomy and intensity modulated radiation therapy became more prevalent during this time [8,9], active surveillance became more popular as an alternative to radiation or surgery, and ADT use declined [9]. Prior studies on the decline of ADT utilization have implicated the MMA [23], though alternative theories such as improved patient outcomes from radiation and surgery have been proposed [23,28]. Therefore, the combined effect of lower payments and utilization of ADT and the increasing rate of active surveillance may have led to a decline in prostate cancer spending.

In contrast, the per-patient cost of colon cancer sharply rose from 2003 to 2005. This may be attributable to the utilization of more expensive chemotherapeutic drug regimens, biologics, and ancillary drugs such as hematopoietic growth factors [29-31]. For example, a prior analysis has suggested that the approval and uptake of folinic acid, Fluorouracil, Oxaliplatin regimen (FOLFOX) was responsible for a 14 percent increase in the cost of treating colorectal cancer [30]. Though associated with improved survival, the cost-effectiveness of these newer drug regimens have been called into question [32].

Data for lung cancer treatment patterns over this time period are conflicting. General trends include constant or declining radiation and surgery utilization over time, which could be due to the opposing forces of better staging (for example, increased PET scan utilization since 2000 led to a decrease in futile resection of metastatic disease [44]) and advancements in radiation and surgical techniques that allow for the treatment of sicker patients [45]. Finally, although some studies showed an increase in chemotherapy use [44], the development of new drug classes did not appear to strongly raise costs for lung cancer care within some populations [46].

Our study has several limitations. First, our data only include costs for physician and supplier services for FFS Medicare beneficiaries, so it excludes Medicare Advantage patients. Because the costs are from Medicare’s perspective, the data also exclude out-of-pocket expenditures and co-insurance from the beneficiary. Cancer drugs covered by Part D, such as hormone therapy for breast cancer treatment, are also excluded. Although carrier claims do not encompass all of Medicare’s cancer expenditures, they constitute a large proportion of cancer expenditures [2], and prior studies have used them to track utilization trends [19,47,48]. Second, we may have underestimated cancer-related costs since we cannot capture the treatment for cancer-related comorbidities that are not billed as treatment for the cancer directly. Conversely, it is possible that
we overestimated cancer costs. Costs unrelated to cancer care would be included in our data if physicians incorrectly billed cancer as the principal diagnosis code for a claim. Prior studies report high sensitivity but low specificity of principal diagnosis codes [49]. Third, our data do not take into account the increasing cost of long-term survivorship care as cancer treatments improve and patients live longer [50]. Nevertheless, our findings are a relevant assessment of initial cancer treatment, which represents in some cancer types the most expensive period of care and in all cancer types a significant driver of overall cancer costs [1,2,12].

Finally, perhaps the greatest limitation of our analysis is that we did not include facility charges from hospital-based outpatient offices. Therefore, the overall trends toward slower payment growth that we observed may be partially attributable to the shift in chemotherapy administration from a physician’s freestanding facility (included in the accounting of physician service costs) to the hospital outpatient setting (where facility fees are not included in physician service costs) [51]. Prior studies have shown that freestanding facility-based chemotherapy claims represented 86.5 percent of chemotherapy claims in 2005, but only 67 percent in 2011 [51]. This coincides with the time period we observe stabilizing costs, and its effect cannot be measured with our data.

However, because physicians submit claims for each procedure they perform and because physician services represent the majority of all FFS claims [52], physician reimbursement trends provide a reasonable proxy for treatment patterns over time. Furthermore, this study isolates provider-based costs from institutional costs due to hospice care, skilled nursing facilities, or facility fees. Despite any potential shift in medical treatment from freestanding facilities to hospital-based outpatient facilities, the sharp decline in the percent of prostate cancer charges reimbursed relative to other disease sites provides significant evidence that Medicare reimbursement policies can play a significant role in controlling costs.

CONCLUSIONS

Our analysis suggests that the cost of physician services for cancer care in the Medicare FFS population has plateaued in recent years, driven partially by a decline in reimbursement for prostate cancer care and a declining incidence of colon and prostate cancer. This effect can also be partially attributed to a shift in site of service (from freestanding center to hospital-based outpatient center). Since the elderly account for more than half of all cancer cases in the United States and physician services constitute a large portion of Medicare cancer spending, this basic analysis provides a broad look at cancer spending for the four major cancer sites during a period of national concern regarding health care spending.

Our analysis provides a starting point for analyzing cancer costs by disease site. Due to timing differences in relevant reimbursement policies, technology adoption, and epidemiological factors, it is reasonable to suspect that aggregate cost trends vary across cancer sites. By adjusting for incidence trends, we have shown that expenditures for cancer costs are not monolithic. Our data and prior literature suggest multiple etiologies for these differences that should be further explored in future work.

Acknowledgments: The authors thank CMS and the NCI’s SEER program for preparing the data and ResDAC for technical support.

REFERENCES

1. Mariotto AB, Robin Yabroff K, Shao Y, Feuer EJ, Brown ML. Projections of the Cost of Cancer Care in the United States: 2010–2020. J Natl Cancer Inst. 2011;103(2):117-28.
2. Stockdale H, Guilloy K. Why Cancer Patients Depend on Medicare for Critical Coverage. American Cancer Society Cancer Action Network (ACS CAN) [Internet]. 2013. Available from: http://www.acscan.org/content/wp-content/uploads/2013/06/2013-Medicare-Chartbook-Online-Version.pdf.
3. Medicare & Medicaid Statistical Supplement. Centers for Medicare & Medicaid Services [Internet]. Available from: http://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareMedicaidStatSupp/index.html.
4. American College of Physicians Policy on Provider-Based Billing. American College of Physicians [Internet]. 2013. Available from: http://www.acponline.org/acp_policy/policies/provider_based_billing_2013.pdf.
5. Buntin MJ, Escarce JJ, Goldman D, Kan H, Laugesen MJ, Shekelle P. Increased Medicare expenditures for physicians’ services: what are the causes? Inquiry. 2004;41(1):83-94.
6. Hsia RY, Akosa Antwi Y, Nath JP. Variation in charges for 10 common blood tests in California hospitals: a cross-sectional analysis. BMJ Open. 2014;4(8):e005482.
7. Butler EN, Chawla N, Lund J, Harlan LC, Warren JL, Yabroff KR. Patterns of Colorctal Cancer Care in the United States and Canada: A Systematic Review. J Natl Cancer Inst Monogr. 2013;2013(46):13-35.
8. Nguyen PL, Gu X, Lipsitz SR, ChoueiRI TK, Choi WW, Lei Y, et al. Cost Implications of the Rapid Adoption of Newer Technologies for Treating Prostate Cancer. J Clin Oncol. 2011;29(12):1517-24.
9. Dinan MA, Robinson TJ, Zagar TM, Scales CD Jr., Curtis LH, Reed SD, et al. Changes in initial treatment for prostate cancer among Medicare beneficiaries, 1999-2007. Int J Radiat Oncol Biol Phys. 2012;82(5):e781-6.
10. Shen X, Showalter TN, Mishra MV, Barth S, Rao V, Levin D, et al. Radiation Oncology Services in the Modern Era: Evolving Patterns of Usage and Payments in the Office Setting for Medicare Patients From 2000 to 2010. J Oncol Pract. 2014;10(4):e201-7.
11. Warren JL, Yabroff KR, Meekins A, Topor M, Lamont EB, Brown ML. Evaluation of Trends in the Cost of Initial Cancer Treatment. J Natl Cancer Inst. 2008;100(12):888-97.
12. Yabroff KR, Lamont EB, Mariotto A, Warren JL, Topor M, Meekins A, et al. Cost of Care for Elderly Cancer Patients in the United States. J Natl Cancer Inst. 2008;100(9):630-41.
13. Cancer Trends Progress Report. National Cancer Institute [Internet]. Available from: http://progressreport.cancer.gov/.
14. Medicare Enrollment Reports. Centers for Medicare & Medicaid Services [Internet]. Available from: https://www.cms.gov/Research-Statistics-Data-and-Systems/Statistics-Trends-and-Reports/MedicareEnrpts/index.html?redirect=/medicareenrpts.
15. About the SEER Program. National Cancer Institute [Internet]. Available from: http://seer.cancer.gov/about/index.html.
16. Surveillance Research Program. National Cancer Institute SEER*Stat Software. 8.1.5 edition.
17. Surveillance, Epidemiology, and End Results (SEER) Program. Site Recode ICD-O-3.WHO 2008 Definition. National Cancer Institute [Internet]. Available from: http://seer.cancer.gov/siterecode/icdo3_dwhome.html.

18. Description of NCHS-CMS Medicare Linkage. Centers for Disease Control [Internet]. 2010. Available from: http://www.cdc.gov/nchs/data/datalinkage/description_of_nchs_cmms_medicare_linkage_SEP2010.pdf.

19. McBean M. Using the Carrier File. ResDAC [Internet]. 2012. Available from: http://www.resdac.org/training/workshops/intro-medicare/media.

20. Crawford M, Church J. CPI Detailed Report Data for April 2014. Bureau of Labor Statistics. Consumer Price Index [Internet]. Available from: http://www.bls.gov/cpi/cpid1404.pdf.

21. Yang DX, Gross CP, Soulos PR, Yu JB. Estimating the magnitude of colorectal cancers prevented during the era of screening: 1976 to 2009. Cancer. 2014;120(18):2893-901.

22. U.S. Preventive Services Task Force. Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149(3):185-91.

23. Shahinian VB, Kuo YF, Gilbert SM. Reimbursement policy and androgen-deprivation therapy for prostate cancer. N Engl J Med. 2010;363(19):1822-32.

24. Painter MR. Reimbursement issues with hormonal therapies for prostate cancer. Rev Urol. 2005;7 Suppl 5:S44-7.

25. Medicare Reimbursement for Lupron. Department of Health and Human Services Office of Inspector General [Internet]. January 2004. Available from: https://oig.hhs.gov/oei/reports/oei-03-03-00250.pdf.

26. Levinson DR. Least Costly Alternative Policies: Impact on Prostate Cancer Drugs Covered Under Medicare Part B (OEI-12-12-00210). Department of Health and Human Services Office of Inspector General, 2012 [Internet]. Available from: https://oig.hhs.gov/oei/reports/oei-12-12-00210.pdf.

27. Least Costly Alternative Policy Changes. American Urological Association [Internet]. [cited 2015 April 28]. Available from: http://www.auanet.org/resources/least-costly-alternative-policy-changes.cfm.

28. Chang SL, Liao JC, Shinghal R. Decreasing use of luteinizing hormone-releasing hormone agonists in the United States is Independent of Reimbursement Changes: A Medicare and Veterans Health Administration claims analysis. J Urol. 2009;182(1):255-60; discussion 61.

29. Ferro SA, Myer BS, Wolff DA, Poniewierski MS, Culakova E, Cosler LE, et al. Variation in the cost of medications for the treatment of colorectal cancer. Am J Manag Care. 2008;14(11):717-25.

30. Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of New Drugs and Biologics on Colorectal Cancer Treatment and Costs. J Oncol Pract. 2011;7(35):e360-7s.

31. Metropol NJ, Schulman KA. Cost of Cancer Care: Issues and Implications. J Clin Oncol. 2007;25(2):180-6.

32. Howard DH, Kauh J, Lipscomb J. The value of new chemotherapeutic agents for metastatic colorectal cancer. Arch Intern Med. 2010;170(6):537-42.

33. Parikh AA, Ni S, Koyama T, Pawlik TM, Penson D. Trends in the multimodality treatment of resectable colorectal liver metastases: an underutilized strategy. J Gastrointest Surg. 2013;17(11):1938-46.

34. Roberts KB, Soulos PR, Herrin J, Yu JB, Long JB, Dostaler E, et al. The adoption of new adjuvant radiation therapy modalities among Medicare beneficiaries with breast cancer: clinical correlates and cost implications. Int J Radiat Oncol Biol Phys. 2013;85(5):1186-92.

35. Tuttle TM, Rueth NM, Abbott A, Virmig BA. Trends in the local treatment of breast cancer: should we be worried? J Surg Oncol. 2011;103(4):313-6.

36. Yang RL, Newman AS, Lin IC, Reinkne CE, Karakousis GC, Czernecki BJ, et al. Trends in immediate breast reconstruction across insurance groups after enactment of breast cancer legislation. Cancer. 2013;119(13):2462-8.

37. Kennedy T, Stewart AK, Bilimoria KY, Patel-Parekh L, Sener SF, Winchester DP. Treatment trends and factors associated with survival in T1aN0 and T1bN0 breast cancer patients. Ann Surg Oncol. 2007;14(10):2918-27.

38. Shiib YC, Elting LS, Halpern MT. Factors associated with immunotherapy use among newly diagnosed cancer patients. Med Care. 2009;47(9):948-58.

39. Verkooyden HM, Bouchardy C, Vinh-Hung V, Rapiti E, Hartman M. The incidence of breast cancer and changes in the use of hormone replacement therapy: A review of the evidence. Maturitas. 2009;64(2):80-5.

40. Breen N, Cronin KA, Tiro JA, Meissner HI, McNeel TS, Sabatino SA, et al. Who was the drop in mammography rates in 2005 associated with the drop in hormone therapy use? Cancer. 2011;117(24):5450-60.

41. Parthan A, Santos E, Becker L, Small A, Lalla D, Brammer M, et al. Health care utilization and costs by site of service for nonmetastatic breast cancer patients treated with trastuzumab. J Manag Care Spec Pharm. 2014;20(5):485-93.

42. Hershman DL, Wilde ET, Wright JD, Buono DL, Kalinsky K, Malin JL, et al. Uptake and economic impact of first-cycle colony-stimulating factor use during adjuvant treatment of breast cancer. J Clin Oncol. 2012;30(8):806-12.

43. Ribeiro JT, Macedo LT, Curigliano G, Fumagalli L, Locatelli M, Dalton M, et al. Cytotoxic drugs for patients with breast cancer in the era of targeted treatment: back to the future? Ann Oncol. 2012;23(3):547-55.

44. Dinan MA, Curtis LH, Carpenter WR, Biddle AK, Abernethy AP, Patz EF, Jr., et al. Redistribution of health care costs after the adoption of positron emission tomography among Medicare beneficiaries with non-small-cell lung cancer, 1998-2005. J Thorac Oncol. 2014;9(4):512-8.

45. Vest MT, Herrin J, Soulos PR, Decker RH, Tanoue L, Michaud G, et al. Use of new treatment modalities for non-small cell lung cancer in the Medicare population. Chest. 2013;143(2):429-35.

46. Bell AM, Corral M, Penrod JR, Zhang Y, Frei CR, Ryan L, et al. New Drugs Not Major Cost Drivers for Lung Cancer Care. American Journal of Pharmacy Benefits. 2014;6(3).

47. Kwan SW, Kerlan RK Jr., Sunshine JH. Utilization of interventional oncology treatments in the United States. J Vasc Interv Radiol. 2010;21(7):1054-60.

48. Pearlman AS, Ryan T, Picard MH, Douglas PS. Evolving trends in the use of echocardiography: a study of Medicare beneficiaries. J Am Coll Cardiol. 2007;49(23):2283-91.

49. Freeman JL, Zhang D, Freeman DH, Goodwin JS. An approach to identifying incident breast cancer cases using Medicare claims data. J Clin Epidemiol. 2000;53(6):605-14.

50. DeSantis CE, Lin CC, Mariotto AB, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics, 2014. CA Cancer J Clin. 2014;64(4):252-71.

51. Vandervelde A, Miller H, Younts J. Impact on Medicare Payments of Shift in Site of Care for Chemotherapy Administration. Berkeley Research Group [Internet]. Available from: http://www.communityoncology.org/UserFiles/BRG_340B_SiteOfCare_ReportF_6-9-14.pdf.

52. Medicare Tables & Reports. Chronic Conditions Data Warehouse [Internet]. Available from: https://www.cww-data.org/web/guest/medicare-tables-reports.